151
Participants
Start Date
March 31, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
NRX-1074 1 mg
Single intravenous administration of 1 mg into arm on Day 0
Placebo
Single intravenous injection into the arm on Day 0
NRX-1074 5 mg
Single intravenous injection of 5 mg into the arm on Day 0
NRX-1074 10 mg
Single intravenous injection of 10 mg into the arm on Day 0
New York State Psychiatric Institute, New York
Mount Sinai School of Medicine, Elmsford
Psychiatric Alliance of the Blue Ridge, Charlottesville
Research Strategies Memphis, Memphis
Lindner Center of HOPE, Mason
Psychiatric Medicine Associates, Skokie
Psychiatric Care and Research Center, O'Fallon
University of Kansas School of Medicine Clinical Trial Unit, Wichita
Research Across America, Dallas
Lifetree Clinical Research, Salt Lake City
Pacific Research Partners, Oakland
Boston Clinical Trials, Inc., Roslindale
Naurex, Inc, an affiliate of Allergan plc
INDUSTRY